Tactile Medical斥資300萬美元獲ElastiMed MyoSleeve獨家美國分銷權，進軍VA/DoD市場

EX-99.1
2
tm2620304d1_ex99-1.htm
EXHIBIT 99.1

 

 

Exhibit 99.1

 

Tactile Medical Enters Exclusive U.S. Distribution
Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients

 

Discreet, Battery-Powered Device Reaches Patients
at Earlier Stages of Disease Progression

 

MINNEAPOLIS, July 13, 2026 (GLOBE NEWSWIRE)
-- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology
company providing therapies for people with chronic disorders, today announced it has entered into an exclusive distribution agreement
with ElastiMed, Inc. to bring MyoSleeve™, its discreet, wearable non-pneumatic compression device for the lower leg, to Department
of Veterans Affairs (VA) and Department of Defense (DoD) patients across the United States. MyoSleeve expands Tactile Medical’s
established market-leading portfolio by providing a new treatment option for appropriately selected patients in earlier stages of chronic
swelling who may not yet require more intensive compression therapy. MyoSleeve may also be appropriate as a complementary treatment to
a traditional pneumatic compression device and for patients who struggle with conservative therapy, or those with mobility-limiting cases.

 

Wrapped around the calf with the ability to be worn beneath clothing,
MyoSleeve uses electroactive polymer technology to deliver dynamic compression through flexible bands that contract in sequence. The battery-powered
device is designed as an all-in-one therapy option, operating without tubing, cords, or an external controller, and quietly delivers intermittent
therapy while patients go about daily activities. MyoSleeve has received U.S. Food and Drug Administration 510(k) clearance and is
indicated for the treatment of chronic swelling, including chronic edema, lymphedema, and venous insufficiency.

 

Under the agreement, Tactile Medical holds exclusive U.S. distribution
rights for MyoSleeve within the VA and DoD systems. In connection with these exclusive distribution rights, the Company made an upfront
payment of $3 million to ElastiMed. The Company also committed to certain minimum purchase obligations and marketing and sales promotion
as it supports ElastiMed’s growth. The Company expects to leverage its established sales organization, billing and payment expertise,
and patient support infrastructure to drive MyoSleeve commercialization and support ongoing market access initiatives. MyoSleeve is available
by prescription, and appropriate patient selection is determined by the treating clinician.

 

“Our agreement with ElastiMed adds a differentiated, wearable
compression option to Tactile Medical’s portfolio and reflects our strategy of expanding access to patient-focused solutions across
the continuum of chronic swelling care,” said Sheri Dodd, Chief Executive Officer of Tactile Medical. “For the right patient,
MyoSleeve offers unobtrusive compression therapy that fits into daily life, giving patients the freedom to stay mobile while engaged in
their own care.”

 

"Partnering with Tactile Medical gives MyoSleeve a direct path
to certain patients with chronic swelling who want to stay active while getting the treatment they need,” said Omer Zelka, Chief
Executive Officer of ElastiMed. “It is the first ambulatory all-in-one, cable-free, clinical-grade solution for patients with venous
and lymphatic conditions. This partnership enables the first commercial introduction of MyoSleeve through a trusted and market-leading
medical device partner."

 

  

  

 

 

"Compression therapy is not one-size-fits-all. Clinicians achieve
the best outcomes when they have a range of options that can be matched to disease severity, anatomy, and lifestyle," said Tony
Gasparis, MD, Chief Medical Officer of Tactile Medical. "MyoSleeve introduces an important new option for appropriately selected
patients with lower-leg swelling, offering active compression that is well-suited for earlier stages of disease, where consistent therapy
adherence is key to slowing disease progression. Importantly, MyoSleeve is designed to complement — not replace — advanced
pneumatic compression therapies, which remain the standard of care for patients with more extensive or advanced disease."

 

For more information about MyoSleeve, please visit https://tactilemedical.com/myosleeve/.

 

About Tactile Systems Technology, Inc. (DBA Tactile Medical)

 

Tactile Medical is a leader in developing and
marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency
and chronic inflammatory lung disease by helping them live better and care for themselves. Tactile Medical collaborates with clinicians
to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life
for tens of thousands of patients each year.

 

About ElastiMed, Inc.

 

ElastiMed is a commercial-stage medical device
company developing wearable therapeutic devices based on electroactive polymer (EAP) technology, designed to deliver dynamic compression
in a comfortable, low-profile, and easy-to-use form.

 

Investor Inquiries:

 

Sam Bentzinger

Gilmartin Group

[email protected]